For: | Gupta T, Jarpula NS. Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status. World J Hepatol 2024; 16(3): 353-365 [PMID: 38577535 DOI: 10.4254/wjh.v16.i3.353] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v16/i3/353.htm |
Number | Citing Articles |
1 |
铭阳 唐. Current Research Status and Prospects of Immunotherapy Advances in Hepatocellular Carcinoma. Advances in Clinical Medicine 2025; 15(01): 254 doi: 10.12677/acm.2025.151037
|
2 |
Ioannis Tsomidis, Argyro Voumvouraki, Elias Kouroumalis. Immune Checkpoints and the Immunology of Liver Fibrosis. Livers 2025; 5(1): 5 doi: 10.3390/livers5010005
|
3 |
Xiao-Wei Wang, Yu-Xing Tang, Fu-Xi Li, Jia-Le Wang, Gao-Peng Yao, Da-Tong Zeng, Yu-Lu Tang, Bang-Teng Chi, Qin-Yan Su, Lin-Qing Huang, Di-Yuan Qin, Gang Chen, Zhen-Bo Feng, Rong-Quan He. Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(10): 4244-4263 doi: 10.4251/wjgo.v16.i10.4244
Abstract(190) |
Core Tip(213) |
Full Article(HTML)(1315)
|
Full Article with Cover (PDF)-15821K(36)
|
Audio-2589K(4)
|
Peer-Review Report-181K(22)
|
Answering Reviewers-99K(33)
|
Supplementary Material-666K(25)
|
Full Article (PDF)-15497K(46)
|
Full Article (XML)-170K(23)
|
Times Cited (0)
|
Total Visits (2558)
|
Open
|